Top Page
Somnomed Limited
(Sydney:SOM)
Somnomed Limited (SOM) vs. iShares MSCI Australia ETF (EWA)
Somnomed Limited Business Overview & Revenue Model
Somnomed Limited Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 111.49M | 111.49M | 91.65M | 83.62M | 72.58M | 62.71M |
| Gross Profit | 66.73M | 66.73M | 55.13M | 45.77M | 39.15M | 33.90M |
| EBITDA | 1.58M | 1.58M | -2.33M | 698.39K | 524.53K | 3.57M |
| Net Income | -3.46M | -3.46M | -12.24M | -8.00M | -4.44M | -1.19M |
Balance Sheet | ||||||
| Total Assets | 80.97M | 80.97M | 69.80M | 62.49M | 58.09M | 56.17M |
| Cash, Cash Equivalents and Short-Term Investments | 17.29M | 17.29M | 16.18M | 11.96M | 15.64M | 21.11M |
| Total Debt | 8.03M | 8.03M | 6.72M | 23.51M | 12.01M | 8.91M |
| Total Liabilities | 34.58M | 34.58M | 24.78M | 40.09M | 30.31M | 24.01M |
| Stockholders Equity | 46.39M | 46.39M | 45.02M | 22.40M | 27.79M | 32.16M |
Cash Flow | ||||||
| Free Cash Flow | 5.36M | 5.36M | -7.72M | -10.29M | -6.93M | -1.43M |
| Operating Cash Flow | 7.78M | 7.78M | -6.33M | -3.88M | 1.86M | 2.71M |
| Investing Cash Flow | -3.98M | -3.98M | -5.34M | -6.41M | -8.47M | -4.37M |
| Financing Cash Flow | -3.38M | -3.38M | 16.68M | 6.61M | 2.09M | -6.80M |
Somnomed Limited Technical Analysis
Somnomed Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | AU$1.48B | -40.76 | -44.49% | ― | 55.91% | 22.60% | |
55 Neutral | AU$162.55M | -47.81 | -7.26% | ― | 21.65% | 81.40% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | AU$106.14M | -8.03 | -31.98% | ― | 34.20% | -23.90% | |
50 Neutral | AU$72.91M | -54.35 | -6.35% | ― | 2.23% | -263.16% | |
48 Neutral | AU$71.31M | -3.04 | -74.00% | ― | 23.31% | -17.35% | |
44 Neutral | AU$163.11M | -15.52 | -70.55% | ― | ― | -257.32% |
Somnomed Limited Corporate Events
Somnomed Limited announced a change in the director’s interest, with Amrita Singh Blickstead acquiring 1,700,000 options, increasing her total options to 1,885,000. This change, approved at the Annual General Meeting, reflects the company’s ongoing commitment to aligning its leadership’s interests with its strategic goals, potentially impacting its market position and stakeholder confidence.
Somnomed Limited has announced a change in the director’s interest, with Karen Borg acquiring 1,700,000 options, as approved at the company’s Annual General Meeting. This change reflects an increase in Borg’s stake in the company, potentially signaling confidence in the company’s future performance and strategic direction, which may impact stakeholders’ perceptions and the company’s market positioning.
Somnomed Limited announced the issuance of unquoted equity securities as part of an employee incentive scheme. This issuance includes options with specific expiration dates and exercise prices, which are not immediately quoted on the ASX, indicating a strategic move to motivate and retain key personnel while potentially impacting future financial performance.
SomnoMed Limited announced a change in the director’s interest, with Benjamin Gisz acquiring 200,000 options, increasing his total to 685,000 options. This change, approved at the Annual General Meeting, reflects ongoing adjustments in the company’s leadership holdings, potentially influencing investor perceptions and the company’s strategic direction.
Somnomed Limited has announced a change in the director’s interest, specifically regarding Michael Gordon, who has acquired 200,000 additional options, increasing his total to 885,000 options. This change was approved at the company’s Annual General Meeting and reflects a strategic move to align the director’s interests with the company’s growth objectives, potentially impacting its market positioning positively.
Somnomed Limited has announced a change in the director’s interest, with Andrew Price acquiring 300,000 options. This change, approved at the Annual General Meeting, reflects the company’s ongoing governance and strategic alignment, potentially impacting its operational focus and stakeholder interests.
Somnomed Limited announced a change in the director’s interest, with Gaetano Alfred Gerrard Russo acquiring 600,000 additional options, as approved at the Annual General Meeting. This change reflects a strategic move to align the director’s interests with the company’s growth objectives, potentially impacting the company’s market positioning and stakeholder confidence.
Somnomed Limited has announced the issuance of unquoted equity securities, specifically options with varying expiration dates and exercise prices. This move is likely to impact the company’s financial strategy and market positioning by potentially increasing its capital base and providing incentives for stakeholders.
SomnoMed Limited announced the results of its Annual General Meeting held on November 27, 2025, where all resolutions were passed. The meeting included the adoption of the Remuneration Report and the election and re-election of directors, as well as the issuance of options to various individuals. The successful passing of these resolutions indicates strong support from stakeholders and may positively impact the company’s governance and strategic initiatives.
SomnoMed Limited’s recent announcement highlights the speculative nature of its securities and the inherent risks involved in investing. The company emphasizes that while it aims for continued advancement in its operations, various factors beyond its control could impact future performance, making it crucial for investors to consider their personal circumstances before investing.
SomnoMed Limited announced that the Australian Stock Exchange has advised the company that it is no longer required to submit quarterly activity and cashflow reports. As a result, SomnoMed will transition to half-year and full-year reporting after releasing its Q1 FY26 update on 30 October 2025. This change is expected to streamline the company’s reporting process and may impact how stakeholders track the company’s financial performance.
SomnoMed Limited’s recent presentation at the Canaccord Drug & Devices Conference highlights the company’s ongoing efforts to revolutionize the sleep medicine industry. While the document includes forward-looking statements about future sales and operational advancements, it emphasizes the speculative nature of the company’s securities and the inherent risks involved. Stakeholders are advised to consider their personal financial circumstances before investing, as the company does not guarantee returns or dividend payments.
Somnomed Limited has announced the issuance of unquoted equity securities, including zero exercise price options expiring in 2030 and 2031, as part of its employee incentive scheme. This strategic move is aimed at enhancing employee engagement and aligning their interests with the company’s long-term growth objectives, potentially strengthening its market position and operational capabilities.
SomnoMed Limited has released a proxy form for its upcoming Annual General Meeting scheduled for November 27, 2025. Shareholders are encouraged to appoint proxies and provide voting directions on various items of business, including the adoption of the Remuneration Report and the election or re-election of directors. The release outlines the necessary steps for appointing a proxy, directing votes, and lodging the proxy form, emphasizing the importance of timely submission to ensure participation in the meeting.
SomnoMed Limited has announced its Annual General Meeting (AGM) scheduled for November 27, 2025, in Sydney. The meeting will address several key items including the consideration of financial statements, adoption of the remuneration report, election and re-election of directors, and the issuance of options under the Non-Executive Share Option Plan 2021. Shareholders are encouraged to review proxy forms and voting exclusions are in place for certain resolutions, particularly those involving key management personnel.
SomnoMed Limited has announced a change in the director’s interest, with Benjamin Gisz reducing his indirect shareholding in the company. The transaction involved the sale of 13,211,430 ordinary shares at $0.70 per share, resulting in Gisz holding 54,504,649 ordinary shares post-transaction. This change reflects a significant adjustment in the director’s investment, potentially impacting the company’s market perception and investor confidence.
SomnoMed Limited announced the successful completion of a block trade involving 16,071,430 shares at $0.70 per share on the ASX. This transaction included shares from the SomnoMed employee share trust and TDM Growth Partners, with TDM’s stake in SomnoMed reducing from 31.3% to 25.0%. The sale aimed to diversify SomnoMed’s share register and improve liquidity without diluting existing shareholders, attracting participation from new and existing institutional and retail shareholders.